Up | AC
Home Page
Food and
Drug Administration
Cellular, Tissue and Gene Therapies Advisory Committee Meeting
March 29, 2007
Sponsor: Dendreon Corporation
Disclaimer
The statements contained in this document(s) are those of
the product's sponsor, not FDA, and FDA does not necessarily
agree with the sponsor's statements. FDA has not made a final
determination about the safety or effectiveness of the product
described in this document.
BLA STN 125197/0
Sipuleucel-T is an autologous active cellular immunotherapy indicated for the treatment of men with asymptomatic metastatic androgen independent prostate cancer (AIPC) (pdf)
FDA
Disclaimer
Portions of this document have been determined to be exempt
from disclosure under the Freedom of Information Act (the
FOIA) (5 U.S.C. §552). These redacted portions will appear
as white space on the screen or on the printed page.
Clinical Briefing Document (pdf)
Errata - AC clinical briefing document (htm)
Statistical Briefing Document (pdf)
Errata - AC statistical briefing document (htm)
CMC Briefing Document (pdf)
Errata- Chemistry, Manufacturing and Controls Briefing Document (htm)
Addendum 1: Chemistry, Manufacturing and Controls Briefing Document (htm)
Bibliography (htm)